Lars Erik Kristensen

Also affiliated with Lund University, Frederiksberg Hospital, Copenhagen University Hospital, Parker Hannifin (Germany), Leo Pharma (Denmark), Parker Hannifin (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study”.

Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study

Annals of the Rheumatic Diseases(2025)10.1136/ard-2024-226129

N/A

0.165DataRank · unranked

2 citations

Sabrina Mai Nielsen, Esben Malm, Daniel E. Furst, Josef S Smolen, Peter C. Taylor +7 more

Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors

BMJ Open(2021)10.1136/bmjopen-2021-049850

N/A

0.104DataRank · unranked

1 citations

Sabrina Mai Nielsen, Johannes I. Berg, John P. A. Ioannidis, Josef S Smolen, Peter C. Taylor +6 more